Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Non-Current Liabilities (2019 - 2025)

BridgeBio Pharma's Total Non-Current Liabilities history spans 7 years, with the latest figure at $2.9 billion for Q2 2025.

  • For Q2 2025, Total Non-Current Liabilities rose 52.35% year-over-year to $2.9 billion; the TTM value through Jun 2025 reached $2.9 billion, up 52.35%, while the annual FY2024 figure was $2.4 billion, 26.2% up from the prior year.
  • Total Non-Current Liabilities for Q2 2025 was $2.9 billion at BridgeBio Pharma, up from $2.5 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $2.9 billion in Q2 2025 and bottomed at $1.5 billion in Q1 2021.
  • The 5-year median for Total Non-Current Liabilities is $1.8 billion (2022), against an average of $1.9 billion.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 216.68% in 2021 before it fell 0.81% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.9 billion in 2021, then decreased by 0.81% to $1.8 billion in 2022, then rose by 2.28% to $1.9 billion in 2023, then grew by 26.2% to $2.4 billion in 2024, then increased by 20.26% to $2.9 billion in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Total Non-Current Liabilities are $2.9 billion (Q2 2025), $2.5 billion (Q1 2025), and $2.4 billion (Q4 2024).